PML targeting eradicates quiescent leukaemia-initiating cells

The PML tumour suppressor gene is involved in the development of some forms of leukaemia. New research has identified a role for PML in the quiescence and maintenance of haematopoietic stem cells and of leukaemia-initiating cells. PML can be targeted by arsenic trioxide and was shown to eliminate leukaemia-initiating cells, supporting its use as an anti-leukemia therapy.